A 32-year-old woman presents with severe dysmenorrhea, deep dyspareunia, and a 3-year history of infertility. Transvaginal ultrasound shows a bulky, heterogeneous uterus with ill-defined junctional zones and no discrete nodules. Regarding adenomyosis, all of the following statements are correct EXCEPT:

Question

Accepted Answer

C. Adenomyosis is primarily an estrogen-independent condition, unlike endometriosis, and does not respond to hormonal therapies targeting estrogen synthesis. ## Adenomyosis: Pathology, Diagnosis, and Management

**Key Point:** Adenomyosis is characterized by benign invagination of basalis layer endometrium into the myometrium, causing a diffusely enlarged, boggy uterus with abnormal contractility.

### Pathophysiology

#### Mechanism of Invasion

1. **Disruption of junctional zone (JZ)** — Loss of normal endometrial–myometrial interface
2. **Invagination of basalis endometrium** — Penetration into inner myometrium (typically inner third)
3. **Myometrial remodeling** — Smooth muscle hyperplasia, fibrosis, and abnormal innervation
4. **Angiogenesis and lymphangiogenesis** — Increased vascularity and lymphatic proliferation

#### Molecular Features

| Feature | Adenomyosis |
|---------|-------------|
| **Estrogen receptor (ER)** | ↑ expression |
| **Progesterone receptor (PR)** | ↓ (especially PR-B) → **Progesterone resistance** |
| **Aromatase** | ↑ (local estrogen synthesis) |
| **Prostaglandins (PGE₂, PGF₂α)** | ↑↑ (↑ COX-2 expression) |
| **Vasopressin** | ↑ (abnormal myometrial contractions) |
| **Nerve fiber density** | ↑↑ (innervation) |

**High-Yield:** Adenomyosis IS estrogen-dependent. Ectopic endometrium in adenomyosis expresses high aromatase, producing local estrogen. It also shows progesterone resistance, making it responsive to estrogen-suppressive therapies (GnRH agonists, progestins, aromatase inhibitors).

### Clinical Presentation

- **Dysmenorrhea** — Secondary, progressive, severe
- **Menorrhagia/Metrorrhagia** — Heavy or prolonged menses
- **Deep dyspareunia** — Due to myometrial thickening and inflammation
- **Infertility** — Impaired endometrial receptivity, abnormal uterine contractions, altered immune milieu
- **Uterine tenderness** — On bimanual examination

**Clinical Pearl:** Unlike endometriosis (which causes discrete lesions), adenomyosis causes **diffuse myometrial involvement** with a characteristic boggy, enlarged uterus.

### Diagnosis

#### Transvaginal Ultrasound (TVUS)

- Junctional zone thickening: **>12 mm** (abnormal)
- Ill-defined or irregular junctional zone
- Heterogeneous myometrial echotexture
- Myometrial cysts or striations
- Asymmetric myometrial thickening

#### MRI (Gold Standard)

- **T2 hypointense lesions** in myometrium (hemosiderin from microhemorrhages)
- **Junctional zone thickening >12 mm**
- **Junctional zone irregularity** (disrupted interface)
- High sensitivity (70–90%) and specificity (80–90%)

**Mnemonic:** **FIGO 2018 Adenomyosis Imaging Criteria** — **JZ** (Junctional Zone) abnormalities on MRI are diagnostic.

### Treatment Options

```mermaid
flowchart TD
  A[Adenomyosis diagnosed]:::outcome --> B{Fertility desired?}:::decision
  B -->|No| C[Medical management first-line]:::action
  C --> D["NSAIDs, COX-2 inhibitors"]:::action
  C --> E["Progestins: MPA, LNG-IUS, dienogest"]:::action
  C --> F["GnRH agonists ± add-back"]:::action
  C --> G["Aromatase inhibitors (letrozole, anastrozole)"]:::action
  B -->|Yes| H["Assisted reproduction (IVF)"]:::action
  H --> I["Consider GnRH agonist pre-treatment"]:::action
  C --> J{Refractory to medical Rx?}:::decision
  J -->|Yes| K["Hysterectomy (definitive)"]:::action
  J -->|No| L["Continue medical management"]:::action
```

**High-Yield:** Adenomyosis is **estrogen-dependent and progesterone-resistant**, making it responsive to:
- Estrogen-suppressive agents (GnRH agonists, aromatase inhibitors)
- Progestin-based therapies (leveraging higher local concentrations to overcome resistance)
- NSAIDs (targeting elevated prostaglandins)

### Why the Marked Answer is Incorrect

The statement "Adenomyosis is primarily an estrogen-independent condition...and does not respond to hormonal therapies" is **FALSE**. Adenomyosis is **estrogen-dependent** (via high aromatase expression and ER upregulation) and **does respond** to:
- GnRH agonists (suppress ovarian estrogen)
- Aromatase inhibitors (block local estrogen synthesis)
- High-dose progestins (overcome progesterone resistance)

This is a critical distinction and a common exam trap.

[cite:Robbins 10e Ch 22; Harrison 21e Ch 382; FIGO 2018 Classification]

Answer

A. Adenomyosis is associated with elevated prostaglandin levels in the endometrium and myometrium, contributing to dysmenorrhea and abnormal uterine contractions

Answer

B. Adenomyosis results from invagination of basalis layer endometrium into the myometrium, typically involving the inner third of the muscle

Answer

D. Adenomyosis is best diagnosed by MRI, which shows characteristic T2 hypointense lesions and junctional zone thickening >12 mm

Explanation

Practice similar questions